Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 EUR | -1.64% | +0.91% | -22.00% |
04-26 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
Sales 2023 | 6.81M 7.28M 583M | Sales 2024 * | 8.4M 8.98M 719M | Capitalization | 61.51M 65.77M 5.27B |
---|---|---|---|---|---|
Net income 2023 | -7M -7.48M -599M | Net income 2024 * | -9M -9.62M -771M | EV / Sales 2023 | 9.11 x |
Net cash position 2023 * | 19.75M 21.12M 1.69B | Net cash position 2024 * | 16.1M 17.21M 1.38B | EV / Sales 2024 * | 5.41 x |
P/E ratio 2023 * |
-4.17
x | P/E ratio 2024 * |
-4.67
x | Employees | 48 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.48% |
1 day | -1.64% | ||
1 week | +0.91% | ||
Current month | +7.44% | ||
1 month | +8.94% | ||
3 months | -10.55% | ||
6 months | -31.10% | ||
Current year | -22.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Pascal Sirvent
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/17 |
Sébastien Bessy
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 17/03/19 |
Laurent Lévy
CHM | Chairman | 53 | 28/02/17 |
Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.9 | -1.64% | 42,504 |
25/04/24 | 3.965 | +0.89% | 36,565 |
24/04/24 | 3.93 | +0.13% | 8,807 |
23/04/24 | 3.925 | +1.29% | 54,196 |
22/04/24 | 3.875 | +0.26% | 9,725 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.00% | 65.67M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALVAL Stock